Caricamento...
Spotlight on risankizumab and its potential in the treatment of plaque psoriasis: evidence to date
Psoriasis is a common chronic immune-mediated skin disease, with systemic involvement and significant impact in patients’ quality of life. Several highly specific treatments have been developed over the years, such as tumor necrosis factor-α inhibitors, a nonselective IL-23 inhibitor (ustekinumab),...
Salvato in:
| Pubblicato in: | Psoriasis (Auckl) |
|---|---|
| Autori principali: | , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Dove Medical Press
2018
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6239126/ https://ncbi.nlm.nih.gov/pubmed/30519540 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/PTT.S165943 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|